Subscribe free to our newsletters via your
. Space Travel News .




EPIDEMICS
Search for AIDS cure pushes ahead despite setbacks
by Staff Writers
Melbourne (AFP) July 19, 2014


Study finds promise toward treating HIV and hep C
Washington (AFP) July 19, 2014 - A new hepatitis C drug has shown early promise in patients whose infection with both HIV and hepatitis C has made them traditionally difficult to treat, said a study Saturday.

Patients were given Gilead Sciences' sofosbuvir, a drug approved for the US market in 2013 that has stirred controversy due to its high price tag -- about $1,000 per pill, along with another well-known drug, ribavirin.

The study in the Journal of the American Medical Association's (JAMA) July 23/30 issue included just over 220 people who were treated for either 12 or 24 weeks.

Most of the patients -- between 67 percent and 94 percent depending on the type of hepatitis C they had and whether they had ever been treated for it before -- saw their liver disease disappear and stay away for 12 weeks after they stopped treatment.

The measurement scientists used was known as sustained virologic response (SVR), or what is clinically considered a "cure" of hepatitis C, a serious and often chronic liver disease.

The study ended 12-weeks after treatment ended, so responses beyond that point are unknown.

As many as seven million people worldwide are infected with both human immunodeficiency virus and hepatitis C, according to background information in the article.

Treating both infections is difficult because patients have needed to use interferon for hepatitis C, which interacts poorly with antiretroviral drugs for HIV suppression.

Seven of the 223 in this study discontinued the treatment because of adverse events, most commonly fatigue, insomnia, headache, and nausea.

Researchers noted that the study was not the most rigorous kind. Doctors knew what they were prescribing to patients, and the participants were not randomized to a comparison treatment or placebo.

However, patients "had high rates of sustained HCV virologic response 12 weeks after cessation of therapy," said the study led by Mark Sulkowski of Johns Hopkins University.

"Further studies of this regimen in more diverse populations of coinfected patients are needed."

An accompanying editorial by Michael Saag of the University of Alabama School of Medicine said the drug combination is a "quantum leap forward" in treatment but that its cost remains too high for widespread use.

"When combined with ribavirin, the average wholesale price of a 12-week course of treatment is $94,500 and $189,000 for a 24-week course," he wrote.

"The world simply cannot afford to pay on a 'cost per cure' basis," he added.

"Hopefully, competition among the new products coming to market in the next 18 months will result in substantially lower pricing for the drugs."

Scientists on Saturday vowed to press ahead with their quest for a cure for AIDS, despite losing a veteran colleague and suffering a setback in research.

Addressing a symposium on the search for a cure, Nobel prize winner Francoise Barre-Sinoussi said the death of Joep Lange, a frontline scientist in the 33-year war on AIDS, was a major setback.

"He was firmly believing that a cure for HIV was possible, as we all do," she said of the Dutchman, who was on the Malaysia Airlines Flight MH17 which went down over Ukraine.

"I am convinced that he, like the other members of the HIV community that were in that plane, would have encouraged us to go on."

Barre-Sinoussi, who co-discovered the human immunodeficiency virus (HIV) which causes AIDS, launched the cure campaign several years ago amid skepticism by some that the goal could ever be attainable.

Despite this, optimism has grown, and cure scientists are confident that they know a lot more about HIV.

After being beaten back by antiretroviral drugs, HIV retreats to a tiny number of cells in the body, holing up there as a safe haven, and becomes undetectable in the blood.

But if the drugs are stopped, the virus rebounds within a few weeks, infecting CD4 cells in the immune system and exposing the body once more to dangerous, opportunistic microbes.

The six-day International AIDS Conference in Melbourne, which starts Sunday, will hear more on Monday about the so-called "kick-and-kill" strand in cure research.

The objective is to pinpoint these reservoirs, flush out the virus with powerful drugs and then destroy it.

But a strategy that sparked hopes of a cure -- delivering a powerful dose of drugs at the earliest stage of infection -- has been dealt a blow.

The hopes centered on an American infant, known anonymously as "the Mississippi Baby", who was born with HIV. She was given drugs immediately at birth and the treatment continued for 18 months, when physicians lost track of her.

When doctors next checked her five months later, they found no sign of the virus.

In the run-up to the AIDS conference, though, it was discovered that after the child had lived 27 months without HIV and drugs, the virus had bounced back.

Jack Whitescarver, director of the Office for AIDS Research at the US National Institutes of Health, said "this really demonstrates that we are still in the early days" of research.

"We will continue to make cure research a high priority and use this information to move the scientific agenda forward," he added.

- Bone marrow breakthrough -

Another area of cure research is bone marrow transplants to generate new, uninfected immune cells.

On Saturday, researchers at Australia's University of New South Wales said two men with HIV now had undetectable levels of the virus after receiving bone marrow transplants for cancer.

In one case, the patient had a successful transplant for non-Hodgkin's lymphoma. His donor had one of two possible copies of a gene that gives protection against HIV.

But in the second case, the man had a bone marrow transplant for acute myeloid leukaemia with a donation that did not have the gene protecting against HIV.

Until now, the only person considered to have been cleared of HIV was American Timothy Ray Brown, who had bone marrow transplants in 2007 and 2008. His donor had both copies of the gene that protects against HIV.

Brown was able to stop antiretroviral therapy and remains clear of the virus. However, when two patients in Boston had transplants without the gene mutation, the virus returned after antiretrovirals were stopped.

Sharon Lewin, a leading cure investigator at Melbourne's Monash University, said it was "very premature" to consider the latest research a cure.

"The patients are still on antiviral therapy, so you cannot say that a patient is cured of HIV until you've stopped the treatment," she said.

Millions of lives have been saved by the advent of antiretroviral drugs. Even so, around 35 million people around the world have HIV, a toll that mounts each year.

Wayne Koff, from the International AIDS Vaccine Initiative, said HIV was the most complex virus ever encountered by vaccine developers.

But recent progress in human trials and experiments on lab monkeys showed a vaccine "is possible", he said in an email exchange with AFP.

.


Related Links
Epidemics on Earth - Bird Flu, HIV/AIDS, Ebola






Comment on this article via your Facebook, Yahoo, AOL, Hotmail login.

Share this article via these popular social media networks
del.icio.usdel.icio.us DiggDigg RedditReddit GoogleGoogle








EPIDEMICS
Study finds promise toward treating HIV and hep C
Washington (AFP) July 19, 2014
A new hepatitis C drug has shown early promise in patients whose infection with both HIV and hepatitis C has made them traditionally difficult to treat, said a study Saturday. Patients were given Gilead Sciences' sofosbuvir, a drug approved for the US market in 2013 that has stirred controversy due to its high price tag - about $1,000 per pill, along with another well-known drug, ribavirin. ... read more


EPIDEMICS
Sanctions on Russian launchers confers advantage to others

Orbital launches cargo ship to space station

Arianespace launches O3b Networks via Soyuz rocket

RUAG Space wins major Ariane 5 payload fairing contract

EPIDEMICS
Curiosity Finds Iron Meteorite on Mars

'Dry Ice' Cause of Gullies on Mars

Further Evidence of Dry Ice Gullies on Mars

NASA Mars Orbiter Views Rover Crossing Into New Zone

EPIDEMICS
Landsat Looks to the Moon

Sky-gazers can expect one 'Supermoon' per month for the next three months

NASA LRO's Moon As Art Collection Is Revealed

Solar photons drive water off the moon

EPIDEMICS
Annual Checkout Makes for Great Pluto Preparation

In exactly one year, NASA's New Horizons probe will reach Pluto

What If Voyager Had Explored Pluto?

The PI's Perspective - Childhood's End

EPIDEMICS
Friction from Tides Could Help Distant Earths Survive, and Thrive

Newfound Frozen World Orbits in Binary Star System

Discovery expands search for Earth-like planets

Astronomers discover most Earth-like of all exoplanets

EPIDEMICS
Marshall Propellant Tank Tech Benefits SLS Development

First Angara Test Launch Successful

NASA and Boeing finalize $2.8 million deal to build super powerful rocket

Russia to make fresh attempt to launch new rocket

EPIDEMICS
Chinese moon rover designer shooting for Mars

Yutu designer's bittersweet

Are China's Astronauts Moonbound

Chinese scientists prepare for lunar base life support system

EPIDEMICS
Twin comets discovered by ESA space probe Rosetta

Probe is headed for duck-shaped comet, images show

Burning down to Rosetta comet rendezvous

Deep in the main asteroid belt




The content herein, unless otherwise known to be public domain, are Copyright 1995-2014 - Space Media Network. All websites are published in Australia and are solely subject to Australian law and governed by Fair Use principals for news reporting and research purposes. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA news reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. Privacy Statement All images and articles appearing on Space Media Network have been edited or digitally altered in some way. Any requests to remove copyright material will be acted upon in a timely and appropriate manner. Any attempt to extort money from Space Media Network will be ignored and reported to Australian Law Enforcement Agencies as a potential case of financial fraud involving the use of a telephonic carriage device or postal service.